Skip to content

Study · Not a test of the peptide alone · 2026

7 results

Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.

Ji L, Andersen JD, Benamar M, Ponzani P, Unnikrishnan AG, Vinther S, Rea R

Diabetes, obesity & metabolism5 Aug 2026Cited by 1 (Europe PMC)

PMID42557064 (opens in a new tab)PMCIDPMC13538793 (opens in a new tab)DOI10.1111/dom.70895 (opens in a new tab)PepBankPUB-42557064
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes in COMBINE 1-3, IcoSema (insulin icodec plus semaglutide) versus comparators showed no significant treatment by kidney or liver function subgroup interaction for HbA1c change to week 52.

    In plain wordsIn adults with type 2 diabetes, the HbA1c effect of IcoSema compared with other treatments did not differ by kidney or liver function.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c change by kidney and liver function subgroup (treatment by subgroup interaction)
    Study

    n: not reported in source

    Comparator
    Comparators (pooled)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In COMBINE 1-3, across kidney and liver function subgroups, there were no statistically significant treatment by subgroup interactions for change in glycated haemoglobin (HbA1c) (baseline to week 52), change in body weight (baseline to week 52) or rates of combined clinically significant or severe h…
    1 context sentence
    Summary · context
    This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes in COMBINE 1-3, IcoSema (insulin icodec plus semaglutide) versus comparators showed no significant treatment by kidney or liver function subgroup interaction for body weight change to week 52.

    In plain wordsIn adults with type 2 diabetes, the body weight effect of IcoSema compared with other treatments did not differ by kidney or liver function.

    Peptide
    Semaglutide
    Outcome
    No significant changeBody weight change by kidney and liver function subgroup (treatment by subgroup interaction)
    Study

    n: not reported in source

    Comparator
    Comparators (pooled)
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    In COMBINE 1-3, across kidney and liver function subgroups, there were no statistically significant treatment by subgroup interactions for change in glycated haemoglobin (HbA1c) (baseline to week 52), change in body weight (baseline to week 52) or rates of combined clinically significant or severe h…
    1 context sentence
    Summary · context
    This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes in COMBINE 1-3, IcoSema (insulin icodec plus semaglutide) versus comparators showed no significant treatment by kidney or liver function subgroup interaction for clinically significant or severe hypoglycaemia.

    In plain wordsIn adults with type 2 diabetes, the low blood sugar risk of IcoSema compared with other treatments did not differ by kidney or liver function.

    Peptide
    Semaglutide
    Outcome
    No significant changeClinically significant or severe hypoglycaemia by kidney and liver function subgroup (treatment by subgroup interaction)
    Study

    n: not reported in source

    Comparator
    Comparators (pooled)
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    In COMBINE 1-3, across kidney and liver function subgroups, there were no statistically significant treatment by subgroup interactions for change in glycated haemoglobin (HbA1c) (baseline to week 52), change in body weight (baseline to week 52) or rates of combined clinically significant or severe h…
    1 context sentence
    Summary · context
    This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes in COMBINE 3, IcoSema (insulin icodec plus semaglutide) versus comparators showed a significant treatment by kidney function interaction for reaching HbA1c below 7.0% without weight gain or significant hypoglycaemia; not in COMBINE 1 or 2.

    In plain wordsIn adults with type 2 diabetes, how well IcoSema met a combined HbA1c, weight and low blood sugar goal differed by kidney function.

    Peptide
    Semaglutide
    Outcome
    Not applicableHbA1c below 7.0% without weight gain and without significant hypoglycaemia, by kidney function subgroup (interaction)
    Study

    n: not reported in source

    Comparator
    Comparators (pooled)
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There were statistically significant treatment by kidney function subgroup interactions for the achievement of HbA1c < 7.0% without weight gain and without clinically significant or severe hypoglycaemia in COMBINE 3 (p < 0.05) but not COMBINE 1 or 2
    1 context sentence
    Summary · context
    This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes in COMBINE 1, IcoSema (insulin icodec plus semaglutide) versus comparators showed a significant treatment by liver function interaction for reaching HbA1c below 7.0% without weight gain or significant hypoglycaemia; not in COMBINE 2 or 3.

    In plain wordsIn adults with type 2 diabetes, how well IcoSema met a combined HbA1c, weight and low blood sugar goal differed by liver function.

    Peptide
    Semaglutide
    Outcome
    Not applicableHbA1c below 7.0% without weight gain and without significant hypoglycaemia, by liver function subgroup (interaction)
    Study

    n: not reported in source

    Comparator
    Comparators (pooled)
    Outcome group
    Glycemic control · Liver

    Source sentences

    Summary
    and statistically significant treatment by liver function subgroup interactions in COMBINE 1 (p < 0.05) but not COMBINE 2 or 3.
    1 context sentence
    Summary · context
    This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes in COMBINE 1 and 3, IcoSema (insulin icodec plus semaglutide) versus comparators showed significant treatment by kidney function interactions for mean weekly total insulin dose.

    In plain wordsIn adults with type 2 diabetes, the weekly insulin dose with IcoSema compared with other treatments differed by kidney function in two trials.

    Peptide
    Semaglutide
    Outcome
    Not applicableMean weekly total insulin dose by kidney function subgroup (interaction)
    Study

    n: not reported in source

    Comparator
    Comparators (pooled)
    Outcome group
    Glycemic control · Kidney and urinary

    Source sentences

    Summary
    For COMBINE 1 and 3, there were statistically significant treatment by kidney function subgroup interactions for mean weekly total insulin dose
    1 context sentence
    Summary · context
    This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes in COMBINE 1 and 3, IcoSema (insulin icodec plus semaglutide) versus comparators showed no significant treatment by liver function interaction for mean weekly total insulin dose.

    In plain wordsIn adults with type 2 diabetes, the weekly insulin dose with IcoSema compared with other treatments did not differ by liver function.

    Peptide
    Semaglutide
    Outcome
    No significant changeMean weekly total insulin dose by liver function subgroup (interaction)
    Study

    n: not reported in source

    Comparator
    Comparators (pooled)
    Outcome group
    Glycemic control · Liver

    Source sentences

    Summary
    but not statistically significant treatment by liver function subgroup interactions.
    1 context sentence
    Summary · context
    This post hoc analysis of COMBINE 1-3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once-weekly combination therapy of basal insulin icodec and semaglutide [a glucagon-like peptide-1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05352815

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

Novo Nordisk A/Sn = 1,2911 Jun 2022 to 23 Apr 2024

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 4 Dec 2025
CompletedPhase 3Results postedNCT05259033

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

Novo Nordisk A/Sn = 68311 Apr 2022 to 16 Jan 2024

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 12 Jun 2026
CompletedPhase 3NCT05013229

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Novo Nordisk A/Sn = 67930 Nov 2021 to 14 Nov 2023

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 2 Dec 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.